Quarterly ResultAug 5, 2026, 04:23 PM
Arcutis Q2 Net Income $15.0M; Raises FY26 Sales Guidance to $525M-$540M
AI Summary
Arcutis Biotherapeutics reported strong second-quarter 2026 financial results, achieving a net income of $15.0 million and product revenue of $129.9 million, a 59% increase year-over-year. The company raised its full-year 2026 net product sales guidance to $525 million–$540 million. Additionally, Chief Commercial Officer L. Todd Edwards resigned, effective August 21, 2026, and Robert Lisicki was appointed interim Executive Vice President and Chief Commercial Officer. The company also announced FDA approval for ZORYVE cream 0.3% for pediatric plaque psoriasis and progress in its pipeline.
Key Highlights
- Q2 2026 net income was $15.0 million, or $0.11 per share.
- Q2 2026 product revenue reached $129.9 million, up 59% YoY.
- Raised full-year 2026 net product sales guidance to $525M-$540M.
- L. Todd Edwards resigned as Chief Commercial Officer, effective August 21, 2026.
- Robert Lisicki appointed interim Executive VP and Chief Commercial Officer.
- Received FDA approval for ZORYVE cream 0.3% for pediatric plaque psoriasis.
- FDA accepted sNDA for ZORYVE cream 0.05% for infant atopic dermatitis.
- Generated $12.6 million in positive operating cash flow for Q2 2026.
Price Impact
More from ARQT